Providers

The top-5 most read articles on spinal muscular atrophy (SMA) span novel research in predictive biomarkers, the benefits of newborn screening, and findings that could reshape SMA as a multisystem disorder.

New treatments and adverse events impacting patient quality of life were among the topics of interest in 2024.

Experts at the Council for Affordable Quality Healthcare (CAQH) Connect 2024 emphasized the transformative potential of artificial intelligence (AI) and predictive analytics in addressing health care challenges, advancing equity, and reducing clinician burden.

This survey study finds that most Missouri Medicaid providers had capacity for new patients, even during a period of unprecedented Medicaid enrollment growth.

Read about the diverse array of research presented at this year's meeting, including novel technological advancements and insights into disease progression in multiple sclerosis (MS).

Real-world study compares the efficacy and safety of axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel), finding that axi-cel provides superior progression-free survival but with higher toxicity.

This recent study sheds light on a remaining gap in spinal muscular atrophy (SMA) research and care considerations: the impact of spinal motor neuron (SMN) copy number.

A Yale School of Medicine team has created lists of criteria to help clinicians determine when next-generation sequencing (NGS) is appropriate for a patient with a myeloid neoplasm (MN), and when it is not.

Two posters presented at the 2024 American Society of Hematology meeting bolster evidence supporting the long-term clinical benefits of ruxolitinib for polycythemia vera and chronic graft-vs-host disease.

Researchers developed and tested an assessment tool to measure coordinated care for traumatic brain injury against the criteria of an integrated practice unit.

Long-term data support the safety and efficacy of venetoclax (Venclexta) and obinutuzumab (Gazyva) in chronic lymphocytic leukemia (CLL), though questions remain about which patients would benefit most from the regimen.

Oussama Wazni, MD, Cleveland Clinic, discusses insights from the OPTION trial and their potential implication on guidelines for post-ablation management in atrial fibrillation.

Single-agent, subcutaneous epcoritamab generated deep responses in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL).

The phase 3 AQUILA study showed a 63.1% progression-free rate at 5 years with daratumumab versus 40.8% with active monitoring.

With new CDC data expressing optimism about the epidemic of sexually transmitted infections (STIs), take a look at the current novel approaches in STI care and learn about crucial next steps to combat this public health issue.

Recent insights shed light onto the most effective diagnostic tools for laryngeal myasthenia gravis (MG), a poorly understood and often misdiagnosed condition, is most reliably.

The 6-year mandatory Increasing Organ Transplant Access Model aims to boost kidney transplants and address disparities by incentivizing hospitals, enhancing care coordination, and measuring transplant outcome performance.

The Center on Health Equity & Access highlights news and expert insights on research, social determinants of health, and health policy.

The findings show that increases in serum glial fibrillary acidic protein throughout B-cell depletion therapy are associated with disability worsening despite not relapsing—known as progression independent of relapse activity.

With ponatinib (Iclusig) receiving an accelerated approval from the FDA earlier this year for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), updated guidelines could be on the horizon.

The 2025 Global Initiative for Chronic Obstructive Lung Disease (GOLD) report highlighted climate change, cardiovascular risk, and pulmonary hypertension.

If made official, the proposed rule would give Part D and Medicaid beneficiaries expanded coverage to antiobesity drugs starting in 2026.

The FDA approval marks the first oral solution indicated for patients with different forms of leukemia.

For some patients with myasthenia gravis (MG), activity and sleep were associated with reported fatigue and symptom levels.

A new study shows that COVID-19 infection significantly increases the risk of exacerbation in patients with myasthenia gravis (MG).

Coverage from the IVBM Regional event in Denver, Colorado.

Long-term survival rates for patients with leukemia after hematopoietic cell transplantation (HCT) are encouraging but personalized transplant strategies remain important to improve outcomes.

The SARAH trial was limited to high-risk patients, which the lead investigator said prevented unnecessary exposure to adverse events in patients less at risk of cardiomyopathy.